Medical Articles 12/28

Posted by rob on December 28, 2007 under Uncategorized | Be the First to Comment

Lyl1 Interacts with CREB1 and Alters Expression of CREB1 Target Genes.

A
half-log increase in BCR-ABL RNA predicts a higher risk of relapse in
patients with chronic myeloid leukemia with an imatinib-induced
complete cytogenetic response.

Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia.

The
severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is
associated with polymorphic variation at the IL5RA locus.

Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.

Deregulation of the Wilms’ tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.

Pleiotropic p27(Kip1), BCR-ABL and leukemic stem cell: the trio in concert.

Powered by ScribeFire.

Medical Articles 12/27

Posted by rob on under Uncategorized | Be the First to Comment

A
Prognostic Score for Patients with Acute Leukemia or Myelodysplastic
Syndromes Undergoing Allogeneic Stem Cell Transplantation.

Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders.

Successful bone marrow transplantation for treatment of chronic myeloid leukemia from a donor with mosaic Klinefelter syndrome.

Comparison
of myeloablative and nonmyeloablative hematopoietic stem cell
transplantation for treatment of chronic myeloid leukemia.

Cytogenetic
remissions induced by interferon alpha and imatinib mesylate are
immunologically distinct in chronic myeloid leukemia.

Dynamics
of BCR-ABL kinase domain mutations in chronic myeloid leukemia after
sequential treatment with multiple tyrosine kinase inhibitors.

Most
CML patients who have a suboptimal response to imatinib have low OCT-1
activity: higher doses of imatinib may overcome the negative impact of
low OCT-1 activity.

Acquired hematopoietic stem-cell disorders and mammalian size.

Chemical
proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and
dasatinib reveal novel kinase and nonkinase targets.

Powered by ScribeFire.

home top